Alternative lung cancer screening criteria may increase sensitivity versus current guidelines
“1. In this modeling study, an alternative set of lung cancer screening criteria was more sensitive and specific overall in identifying high-benefit people as compared to the current United States Preventive Services Task Force criteria. 2. The alternative criteria were also more sensitive in identifying high-benefit people among racial and ethnic minorities.”
Kiromic Puts Gamma Delta T-Cells to the Test for Lung Cancer in Deltacel-01 Clinical Trial
“Kiromic BioPharma’s KB-GDT-01 (Deltacel), an investigational allogeneic gamma delta T-cell (GDT) therapy, is currently being evaluated in the phase 1/2 Deltacel-01 clinical trial (NCT06069570) for the treatment of non-small cell lung cancer (NSCLC).1 Following up on World Lung Cancer Day, observed annually on the August 1 by the clinician and patient communities, CGTLive® has decided to take a closer look at this novel cell therapy this month.”
FDA Lifts Partial Clinical Hold on Phase 1 YL202 Trial in NSCLC and Breast Cancer
“The partial clinical hold placed on the phase 1 YL202-INT-101-01 trial (NCT05653752) of YL202 (BNT326) has been lifted by the FDA. This study is evaluating treatment with the antibody-drug conjugate (ADC) in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR mutations or hormone receptor (HR)-positive/HER2-negative breast cancer. Trial enrollment will resume in the US; however, patients will not be enrolled in dose cohorts higher than 3 mg/kg of YL202.”
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
“RYBREVANT® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus Osimertinib. Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT® plus LAZCLUZE™ reduced the risk of disease progression or death by 30 percent versus osimertinib, with a nine-month-longer median duration of response.”
FDA Grants BTD to GSK5764227 for Extensive-Stage Small Cell Lung Cancer
“The FDA has awarded breakthrough therapy designation to the B7-H3–targeted antibody-drug conjugate (ADC), GSK5764227 (HS-20093), for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) that has progressed on or following platinum-based chemotherapy.”
AI tools help uncover connections between radiotherapy for lung cancer and heart complications
“Researchers from Brigham and Women’s Hospital have used artificial intelligence tools to accelerate the understanding of the risk of specific cardiac arrhythmias when various parts of the heart are exposed to different thresholds of radiation as part of a treatment plan for lung cancer.”
International Lung Cancer Experts Seek Public Comments on Updated Molecular Testing Guideline to Improve Patient Selection and Targeted Therapies
“Newswise — ROCKVILLE, MD — August 22, 2024 — The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised 2018 evidence-based guideline, “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors.”
Temple professor raises funds for lung cancer patients
“John Matthews is the founder of Ride Hard Breathe Easy, a nonprofit organization dedicated to raising awareness, assisting lung cancer patients and working to end the stigma associated with the disease.”
Promising lung cancer vaccine trial begins in UK
“A 67-year-old man has become the first person in the UK to try what doctors hope will be a revolutionary new treatment for lung cancer – a vaccine that tells the body how to fight and kill the disease. It uses the same mRNA technology as some Covid jabs to give instructions to the immune system.”
Leal Examines Latest Data for Lurbinectedin and Tarlatamab in ES-SCLC
“Peers & Perspectives in Oncology: Could you explain the recent indirect analysis of lurbinectedin (Zepzelca) vs topotecan in pretreated patients with ES-SCLC who have a chemotherapy-free interval (CTFI) of at least 30 days?”
Video:
US participates in world’s first lung cancer vaccine trials
“A doctor with the Yale Cancer discusses what researchers are hoping to accomplish with upcoming clinical trials.”
